Atrial fibrillation ablation: 1-year 'real-life' outcome with contact force catheter after a single procedure
Autor: | A. Bouharaoua, P. Dieuzaide, Sébastien Prévôt, Alexis Mechulan |
---|---|
Rok vydání: | 2018 |
Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment Atrial fibrillation Atrial arrhythmias Ablation medicine.disease Pulmonary vein Clinical trial Catheter Internal medicine cardiovascular system medicine Cardiology Sinus rhythm cardiovascular diseases Cardiology and Cardiovascular Medicine business Linear ablation |
Zdroj: | Archives of Cardiovascular Diseases Supplements. 10:89 |
ISSN: | 1878-6480 |
DOI: | 10.1016/j.acvdsp.2017.11.240 |
Popis: | Introduction Atrial fibrillation ablation success rate has improved over the years. Data regarding success rate with contact force catheter are only available in clinical trials. The aim of our study was to assess the “real-life” success rate of atrial fibrillation ablation at 1 year using the Smarttouch catheter (Biosense Webster). Methods Patients who underwent first procedure of atrial fibrillation ablation between January 2014 and December 2015 were prospectively enrolled. Patients with paroxysmal atrial fibrillation (PAF) underwent pulmonary vein isolation. Patients with persistent atrial fibrillation (PeAF) had pulmonary vein isolation with linear ablation and/or atrial defragmentation to obtain sinus rhythm. Procedure success rate was defined as free from any arrhythmia during the first year of follow-up. Results Overall, 246 patients (62.6 ± 11 year, 68% males) were enrolled in our study. One hundred and forty eight patients underwent PAF ablation and 99 patients underwent PeAF ablation. Among the PAF patients, 26 had atrial arrhythmias during follow-up (success rate 82.4%). Among the PeAF patients, 33 had atrial arrhythmias during follow-up (success rate 66,6%). Interestingly, 29.79% of patients with no arrhythmia recurrence were still on antiarrhythmic drugs despite our recommendations to stop them at 3 months after the procedure. Conclusion After a single atrial fibrillation ablation with contact force catheter (Smarttouch, Biosense webster), real-life success rate is consistent with clinical trials. Some patients without arrhythmia recurrence were still on antiarrhythmic drugs despite electrophysiologists recommendations. |
Databáze: | OpenAIRE |
Externí odkaz: |